Sickle Cell Disease — Health Literacy - Neurocognitive Screening in Pediatric SCD
Citation(s)
Acquazzino MA, Miller M, Myrvik M, Newby R, Scott JP Attention Deficit Hyperactivity Disorder in Children With Sickle Cell Disease Referred for an Evaluation. J Pediatr Hematol Oncol. 2017 Jul;39(5):350-354. doi: 10.1097/MPH.0000000000000847.
Anie KA Psychological complications in sickle cell disease. Br J Haematol. 2005 Jun;129(6):723-9. Review.
Brandow AM, Zappia KJ, Stucky CL Sickle cell disease: a natural model of acute and chronic pain. Pain. 2017 Apr;158 Suppl 1:S79-S84. doi: 10.1097/j.pain.0000000000000824. Review.
Caldwell EP, Carter P, Becker H, Mackert M The Use of the Newest Vital Sign Health Literacy Instrument in Adolescents With Sickle Cell Disease. J Pediatr Oncol Nurs. 2018 Sep/Oct;35(5):361-367. doi: 10.1177/1043454218767875. Epub 2018 Apr 16.
Daly B, Kral MC, Tarazi RA The role of neuropsychological evaluation in pediatric sickle cell disease. Clin Neuropsychol. 2011 Aug;25(6):903-25. doi: 10.1080/13854046.2011.560190. Review.
Daly, B P., Kral, M. C., & Brown, R. T. (2008). Cognitive and academic problems associated with childhood cancers and sickle cell disease. School Psychology Quarterly, 23(2), 230-242. https://doi.org/10.1037/1045-3830.23.2.230
Davis DW, Jones VF, Logsdon MC, Ryan L, Wilkerson-McMahon M Health promotion in pediatric primary care: importance of health literacy and communication practices. Clin Pediatr (Phila). 2013 Dec;52(12):1127-34. doi: 10.1177/0009922813506607. Epub 2013 Oct 21.
Hardy SJ, Bills SE, Wise SM, Hardy KK Cognitive Abilities Moderate the Effect of Disease Severity on Health-Related Quality of Life in Pediatric Sickle Cell Disease. J Pediatr Psychol. 2018 Sep 1;43(8):882-894. doi: 10.1093/jpepsy/jsy019.
Kawadler JM, Clayden JD, Clark CA, Kirkham FJ Intelligence quotient in paediatric sickle cell disease: a systematic review and meta-analysis. Dev Med Child Neurol. 2016 Jul;58(7):672-9. doi: 10.1111/dmcn.13113. Epub 2016 Mar 31. Review.
Kral MC, Brown RT, Hynd GW Neuropsychological aspects of pediatric sickle cell disease. Neuropsychol Rev. 2001 Dec;11(4):179-96. Review.
McCleary-Jones V Health literacy and its association with diabetes knowledge, self-efficacy and disease self-management among African Americans with diabetes mellitus. ABNF J. 2011 Spring;22(2):25-32.
McClure E, Ng J, Vitzthum K, Rudd R A Mismatch Between Patient Education Materials About Sickle Cell Disease and the Literacy Level of Their Intended Audience. Prev Chronic Dis. 2016 May 12;13:E64. doi: 10.5888/pcd13.150478.
Nobile C, Drotar D Research on the quality of parent-provider communication in pediatric care: implications and recommendations. J Dev Behav Pediatr. 2003 Aug;24(4):279-90. Review.
Schatz J, Finke R, Roberts CW Interactions of biomedical and environmental risk factors for cognitive development: a preliminary study of sickle cell disease. J Dev Behav Pediatr. 2004 Oct;25(5):303-10.
Weekes CV African Americans and health literacy: a systematic review. ABNF J. 2012 Fall;23(4):76-80. Review.
Williams AM, Zent CS, Janelsins MC What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol. 2016 Sep;174(6):835-46. doi: 10.1111/bjh.14211. Epub 2016 Jul 8. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.